Reviva Pharmaceuticals Holdings (RVPH)
NASDAQ:RVPH
Top Page
Reviva Pharmaceuticals Holdings
(NASDAQ:RVPH)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.81
▲(4.81% Upside)
Action:ReiteratedDate:04/03/26
The score is primarily held down by weak financial performance (no revenue, widening losses, and sustained negative cash flow with added uncertainty from inconsistent 2025 figures) and bearish technicals (price well below major moving averages with negative momentum). Valuation provides limited support given the non-meaningful P/E and lack of dividend yield data.
Positive Factors
Pipeline advancement (brilaroxazine Phase 3)
Advancing the lead candidate into a RECOVER-2 Phase 3 program is a durable de-risking step for a clinical-stage biotech. A successful pivotal program would materially change the company’s profile from discovery to potential commercialization and create long-term strategic optionality.
Negative Factors
Pre-revenue with widening losses
A persistent pre-revenue model with widening net losses means the firm must continually access external capital to sustain operations. Ongoing losses erode equity, increase shareholder dilution risk, and constrain the company’s ability to self-fund late-stage development or commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline advancement (brilaroxazine Phase 3)
Advancing the lead candidate into a RECOVER-2 Phase 3 program is a durable de-risking step for a clinical-stage biotech. A successful pivotal program would materially change the company’s profile from discovery to potential commercialization and create long-term strategic optionality.
Read all positive factors
Reviva Pharmaceuticals Holdings (RVPH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.88M
Dividend YieldN/A
Average Volume (3M)14.40M
Price to Earnings (P/E)―
Beta (1Y)1.63
Revenue GrowthN/A
EPS Growth58.55%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.72
Shares Outstanding12,810,377
10 Day Avg. Volume22,198,486
30 Day Avg. Volume14,401,288
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.42M
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.69
Forecast
1Y Price Target
$15.50Price Target Upside1912.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-3.27
Revenue Forecast (FY)N/A
Reviva Pharmaceuticals Holdings Business Overview & Revenue Model
Company Description
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory,...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Reviva does not have publicly disclosed recurring product revenue from commercialized drugs; its operations have historically been funded primarily through financing activities rather than sales (null...
Reviva Pharmaceuticals Holdings Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
28
Negative
Cash Flow
9
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -20.20T | -29.88M | -39.21M | -24.11M | -10.10M |
| Net Income | -19.86T | -29.92M | -39.26M | -24.34M | -8.52M |
Balance Sheet | |||||
| Total Assets | 15.92T | 15.50M | 23.70M | 18.92M | 31.40M |
| Cash, Cash Equivalents and Short-Term Investments | 14.44T | 13.48M | 23.37M | 18.52M | 29.69M |
| Total Debt | 406.88B | 458.15K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 7.28T | 14.69M | 17.98M | 10.53M | 2.72M |
| Stockholders Equity | 8.65T | 812.57K | 5.72M | 8.39M | 28.69M |
Cash Flow | |||||
| Free Cash Flow | -24.59T | -33.54M | -28.32M | -18.96M | -10.67M |
| Operating Cash Flow | -24.59T | -33.54M | -28.32M | -18.96M | -10.67M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 25.56T | 23.65M | 33.17M | 7.79M | 31.60M |
Reviva Pharmaceuticals Holdings Technical Analysis
Negative
0.77
Price Trends
3.27
Negative
6.21
Negative
7.88
Negative
Market Momentum
-0.75
Negative
25.67
Positive
52.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVPH, the sentiment is Negative. The current price of 0.77 is below the 20-day moving average (MA) of 1.09, below the 50-day MA of 3.27, and below the 200-day MA of 7.88, indicating a bearish trend. The MACD of -0.75 indicates Negative momentum. The RSI at 25.67 is Positive, neither overbought nor oversold. The STOCH value of 52.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVPH.
Reviva Pharmaceuticals Holdings Risk Analysis
Reviva Pharmaceuticals Holdings disclosed 61 risk factors in its most recent earnings report. Reviva Pharmaceuticals Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Reviva Pharmaceuticals Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $257.05M | -2.24 | -129.98% | ― | 250.00% | 15.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $34.42M | -1.93 | -226.10% | ― | ― | 48.68% | |
41 Neutral | $9.88M | ― | ― | ― | ― | 58.55% | |
40 Underperform | $32.94M | -1.74 | 774.80% | ― | -8.16% | 22.44% |
* Healthcare Sector Average
RVPH
Reviva Pharmaceuticals Holdings
0.77
-14.75
-95.04%
CVM
Cel-Sci
4.07
-3.10
-43.26%
PSTV
Plus Therapeutics
4.80
-11.19
-69.98%
XBIT
XBiotech
2.33
-0.79
-25.32%
PRLD
Prelude Therapeutics
4.08
3.39
491.30%
COEP
Coeptis Therapeutics Holdings
11.95
2.55
27.13%
Reviva Pharmaceuticals Holdings Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Reviva Pharmaceuticals Announces $10 Million Equity Offering
Positive
Mar 19, 2026
On March 18, 2026, Reviva Pharmaceuticals Holdings, Inc. entered into agreements with institutional investors for a registered public offering of common stock, pre-funded warrants and Series G and H warrants, structured at a public offering price ...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Reviva Pharmaceuticals Announces One-for-Twenty Reverse Stock Split
Negative
Mar 5, 2026
On March 4, 2026, Reviva Pharmaceuticals filed an amendment to its charter to implement a one-for-twenty reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on March 9, 2026, with shares to begin trading on a split-adjust...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Reviva Pharmaceuticals Granted Nasdaq Extension to Regain Compliance
Negative
Jan 23, 2026
Reviva Pharmaceuticals Holdings, which is listed on the Nasdaq Capital Market, has disclosed heightened risks related to maintaining its stock exchange listing after failing to meet Nasdaq’s minimum bid price requirement of $1.00 per share. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.